Coral Laboratories Ltd

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 March 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid persistent operational headwinds and valuation considerations.

Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating fundamentals and increasingly negative technical signals. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical indicators have shifted towards bearish trends. This comprehensive downgrade is driven by four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, primarily driven by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical company’s Mojo Score now stands at 31.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations.

Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating fundamentals and increasingly bearish technical indicators. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical analysis signals a negative trend. This comprehensive review examines the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that triggered the rating change.

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer, reported deeply disappointing third-quarter results for FY2026, with net profit collapsing 54.70% year-on-year to ₹2.78 crores from ₹6.14 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹173.00 crores, saw its stock trading at ₹479.90 on February 13, down 1.41% on the day and languishing 43.60% below its 52-week high of ₹850.90.